Anaplastic Oligodendroglioma
52
5
8
29
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
11 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
15.4%
8 terminated out of 52 trials
78.4%
-8.1% vs benchmark
4%
2 trials in Phase 3/4
38%
11 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (52)
Pediatric Long-Term Follow-up and Rollover Study
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Implantable Microdevice In Primary Brain Tumors
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas